OncoBay Clinical Announces Addition of Anna Averitt as Counsel and Chief Privacy Officer
OncoBay Clinical Continues to Drive a Culture of Compliance
TAMPA, Fla. (March 15, 2021) — OncoBay Clinical, Inc., a full-service boutique contract research organization (CRO) specializing in complex cancer therapies, is pleased to announce the appointment of Anna Averitt as OncoBay Counsel and Chief Privacy officer. In addition to leading the legal organization, in her new role, Anna will be managing legal compliance and will spearhead the implementation of privacy best practices across the organization.
A graduate of Campbell University, School of Law, Anna brings more than 20 years of senior legal experience, having served as Associate Counsel for a global Clinical Research Organization, as well as having supported a number of law firms in the private sector. In addition, she is a Certified Information Privacy Professional/US by the International Association of Privacy Professionals.
“Anna’s proven success providing counsel to diverse organizations, makes her a great addition to the OncoBay senior leadership team,” said Krystyna Kowalczyk, President and CEO of OncoBay”. “Her extensive legal and business operations experience, coupled with her exemplary negotiation skills, will be instrumental to the success of our Biotech Sponsors and to OncoBay directly, as we further our growth and expansion.” “Additionally, Anna’s role as OncoBay’s Chief Privacy Officer reflects OncoBay’s continued commitment to compliance and to the privacy function as a whole”.
“I am delighted to join the OncoBay team at this exciting phase of the company’s growth,” said Anna. “As the ecosystem evolves, OncoBay will remain at the forefront of legal, safety and data compliance”.
To learn more about OncoBay Clinical, please visit www.OncoBay.com.
About OncoBay Clinical
OncoBay Clinical is a boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full- service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As a wholly owned, for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit OncoBay.com and follow us on Facebook, Twitter and LinkedIn.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
###
MEDIA CONTACT:
Richard Busby
OncoBay Clinical, Vice-President Business Development
Phone: 919.604.2329
RBusby@oncobay.com
